Lung adenocarcinoma is a surprisingly complex and diverse disease characterized by malignant neoplasm originating from the glandular epithelium of the lung tissue. These tumors constitute one of the most common forms of lung cancer and usually develop in the peripheral parts of the lung, in contrast to squamous cell carcinoma, which more often occurs in the central parts. Lung adenocarcinoma can manifest itself with various clinical symptoms, such as persistent cough, shortness of breath, and sometimes chest pain. As the disease progresses, metastases to other organs may develop, which significantly worsens the prognosis and makes treatment more difficult.
History of the disease and interesting historical facts
Lung adenocarcinoma was first described in 1926 by the Englishman Hamilton. Since then, the study of this disease has undergone many changes. In the 1950s, research began to focus on the relationship between smoking and cancer. An important milestone was the discovery of genetic mutations related to adenocarcinoma in the 1970s. In the 1980s, new imaging techniques such as CT and PET were developed, which significantly improved the diagnosis of the disease. Thus, the history of lung adenocarcinoma includes not only medical discoveries, but also social aspects related to changing smoking culture.
Epidemiology
Lung adenocarcinoma is the most common type of lung cancer among women and the second most common type among men after squamous cell carcinoma. According to the World Health Organization, the incidence of this type of cancer is steadily increasing. In 2020, more than 2.2 million new cases of adenocarcinoma were registered worldwide. The five-year survival rate is about 15-20% depending on the stage of the disease at diagnosis. In recent years, there has been a trend towards an increase in the incidence among non-smoking women, which requires further research and attention to genetic and environmental factors.
Genetic predisposition to this disease
There are several genetic mutations that have been associated with the development of lung adenocarcinoma. The most significant are mutations in the EGFR, ALK, KRAS, ROS1, and MET genes. For example, the presence of mutations in the EGFR gene may indicate a more aggressive form of the disease. In most cases, patients with a KRAS mutation have a worse outcome precisely because of high rates of resistance to standard treatments. Early detection of such mutations may be critical for choosing the optimal therapeutic strategy, including targeted therapy.
Risk factors for the development of this disease
Risk factors for lung adenocarcinoma can be divided into several categories:
- Physical factors:
- Ionizing radiation
- Work environment with high levels of asbestosis
- Chemical factors:
- Tobacco smoking (both active and passive)
- Exposure to radiation and carcinogens
- Other factors:
- Environmental factors including air pollution
- Family history of lung cancer
This multitude of factors highlights the importance of a comprehensive approach to prevention and early detection of the disease.
Diagnosis of this disease
Diagnosis of lung adenocarcinoma involves several stages, which allows for an accurate diagnosis and stage of the disease. The main symptoms may include:
- A persistent cough that may change in character
- Short or long breathing
- Blood in sputum and/or chest pain
Various laboratory and radiological tests are used to confirm the diagnosis, including:
- Computed tomography (CT) for lung imaging
- Methods of obtaining a biopsy, such as through bronchoscopy or needle biopsy
- Molecular genetic studies to identify specific mutations
Differential diagnosis is important to exclude other lung diseases such as tuberculosis and benign tumors, which also requires the involvement of a qualified physician.
Treatment
Treatment for lung adenocarcinoma depends on the stage of the disease, its characteristics, and the patient's overall health. The main areas of therapy include:
- General treatment:
- Surgical intervention at accessible stages
- Radiation therapy as a restorative or palliative treatment
- Pharmacological treatment:
- Targeted drugs such as EGFR inhibitors
- Immunotherapy for irreversible variants of the disease
- Other types of treatment:
- Palliative care for symptom management in late stages
- Clinical trials for innovative therapies
The development of an individual treatment plan is mandatory based on a comprehensive assessment of the patient's condition.
List of medications used to treat this disease
The medications used for lung adenocarcinoma may vary depending on the individual therapy. Below is a list of the main drugs:
- EGFR inhibitors (eg, Osimertinib)
- ALK inhibitors (eg, Alectinib)
- Antibodies for immunotherapy (eg, Pembrolizumab)
- Chemotherapy drugs (eg, Paclitaxel and Carboplatin)
- Targeted drugs active against KRAS-mutant tumors (eg, Sequinase)
The use of each of these substances should be carried out taking into account the analysis of the mutational profile of the neoplasm.
Disease monitoring
Monitoring the patient's condition with lung adenocarcinoma includes regular follow-up examinations to assess the effectiveness of therapy, detect relapses and possible complications. The prognosis of the disease depends on the stage of the diagnosed cancer and the treatment strategy. In the early stages, survival can reach 70%, while in the later stages it decreases to less than 15%. Complications may include:
- Metastases to distant organs
- Development of pleural effusion
- Pneumonia and other pulmonary complications
High-quality monitoring allows problems to be identified in a timely manner and treatment to be adapted to the patient’s current needs.
Age-related features of the disease
Lung adenocarcinoma has its own age-related characteristics in terms of its course and prognosis. People over 65 years of age often have more aggressive forms of the disease, which is associated with the accumulation of genetic mutations and comorbidities. In young people, due to the relatively low incidence, the disease is often detected at later stages. An important factor is also the state of the immune system, which worsens with age. This is confirmed by data from a 2019 study showing that 60% cases were diagnosed in patients over 60 years of age, while 65% of them suffered from comorbidities, which significantly influenced the choice of treatment.
Questions and Answers
- What are the main symptoms of lung adenocarcinoma? The main symptoms include persistent cough, shortness of breath, blood in the sputum and chest pain.
- How is lung adenocarcinoma diagnosed? Diagnostics include CT scan, bronchoscopy for biopsy and molecular genetic tests.
- What are the risk factors associated with lung adenocarcinoma? The main factors are smoking, high levels of air pollution and infectious lung diseases.
- What is the treatment for lung adenocarcinoma? Treatment may include surgery, chemotherapy, and targeted therapy depending on the stage of the disease.
- What is the prognosis for patients with lung adenocarcinoma? The prognosis depends on the stage of the disease, but in the early stages, survival can be up to 70%.
Advice from Dr. Oleg Korzhikov
Patients often ask about prevention and lifestyle—important aspects that can help improve their condition. First and foremost, the doctor emphasizes the need for regular medical checkups, especially for those at high risk:
- Quitting smoking is the key to reducing your risk.
- Maintaining a healthy lifestyle, including physical activity and a balanced diet, can help improve overall health.
- Regular monitoring by a specialist to promptly identify and treat possible complications.
An exacerbation can cause doubt and fear in patients, but it is important to maintain a positive attitude and actively participate in your own treatment.
